title: Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
abstract: Current research of prostate cancer (PCa) offers a promising way of identifying patients with adverse prognosis who do benefit from radical treatment that can affect quality of life as resections are associated with numerous side-effects. The aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy.
  
  
  
  The study group consisted of 108 patients who underwent radical prostatectomy. PSA was measured in peripheral blood collected preoperativelly. The expression of TMPRSS2-ERG transcript and the expression of miR-23b, miR-26a and miR-221 in formalin-fixed, paraffin-embedded (FFPE) tumor tissues was analyzed by reverse transcription (RT) real-time polymerase chain reaction (PCR).
  
  
  
  Significantly shorter time to recurrence was observed in patients with high expression of TMPRSS2-ERG (p=0.0020). High levels of preoperative PSA (>10.0 ng/ml) proved to be marker of shorter time to recurrence (p=0.0153). The most promising marker of the risk of recurrence after radical prostatectomy was a combination of high level of preoperative serum PSA and high expression of TMPRSS2-ERG fusion transcript in tumor tissue (p=0.0001).
  
  
  
  A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening.
authors.affiliation: Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
authors.forename: Vlastimil
authors.initials: V
authors.lastname: Kulda
authors.affiliation: Department of Nuclear Medicine - Immunoanalytic Laboratory, University Hospital in Pilsen, Pilsen, Czech Republic.
authors.forename: Ondrej
authors.initials: O
authors.lastname: Topolcan
authors.affiliation: Department of Nuclear Medicine - Immunoanalytic Laboratory, University Hospital in Pilsen, Pilsen, Czech Republic.
authors.forename: Radek
authors.initials: R
authors.lastname: Kucera
authors.affiliation: Department of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
authors.forename: Michaela
authors.initials: M
authors.lastname: Kripnerova
authors.affiliation: Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
authors.forename: Kristyna
authors.initials: K
authors.lastname: Srbecka
authors.affiliation: Department of Urology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
authors.forename: Milan
authors.initials: M
authors.lastname: Hora
authors.affiliation: Department of Pathology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
authors.forename: Ondrej
authors.initials: O
authors.lastname: Hes
authors.affiliation: Urocentrum Plzen, Pilsen, Czech Republic.
authors.forename: Jiri
authors.initials: J
authors.lastname: Klecka
authors.affiliation: Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
authors.forename: Vaclav
authors.initials: V
authors.lastname: Babuska
authors.affiliation: Department of Nuclear Medicine - Immunoanalytic Laboratory, University Hospital in Pilsen, Pilsen, Czech Republic.
authors.forename: Milena
authors.initials: M
authors.lastname: Rousarova
authors.affiliation: Institute of Microbiology, v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic.
authors.forename: Veronika
authors.initials: V
authors.lastname: Benson
authors.affiliation: Department of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic martin.pesta@lfp.cuni.cz.
authors.forename: Martin
authors.initials: M
authors.lastname: Pesta
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000235:genetics; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000097:blood / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000235:genetics* / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D016612:Paraffin Embedding; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D012307:Risk Factors
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D035683:MicroRNAs; D015514:Oncogene Proteins, Fusion; D017430:Prostate-Specific Antigen; C525709:MIR221, human; C552430:MIRN23a microRNA, human; C528163:MIRN26 microRNA, human; C515553:TMPRSS2-ERG fusion protein, human; C479341:prostate cancer antigen 3, human
keywords: PCA3; PSA; Prostate cancer; TMPRSS2-ERG; microRNA; prognosis